XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy
SUZHOU, China, March 2, 2026 /PRNewswire/ -- In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its...
G2 Awards 22 Badges to MSA including No 1 for Most Recommended, Competitive Pricing, Expertise and User Satisfaction in the Financial Consulting Category
SHANGHAI, Jan. 16, 2025 /PRNewswire/ -- MSA, a leader in Asia company incorporation and accounting services, today announced that it has been recognized by G2 — the world's largest and most trusted unbiased review platform — as a top-ranked firm...